DDInter1625 DDInter634
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy. As well, emapalumab was given the status of PRIME by the EMA.
Emapalumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lovastatin
Emapalumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Emapalumab {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Emapalumab may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin
Emapalumab may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Emapalumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen